2020 NMD4C Year in Review

covidNMD4C 2020 Year in Review

The NMD4C is proud to be where we are today. It is no easy task to unite a diverse community of stakeholders under a clear and united vision; even more difficult is to do so with the unique challenges every single member of our community faced during 2020.

With the sudden onset of obstacles early in the year, we are grateful for the outstanding work and involvement from everyone who was a part of the network in 2020. Thanks to the resilience and drive of our Steering Committee, Investigators, Collaborators, and members, we are in the position to celebrate a year of success and meaningful gains towards our network goals.

We look forwards to growing as a network with all of you in the coming year, and in the meantime invite you to reflect on some of the highlights from the past year.

Wishing everyone a happy holiday, and we will see you in 2021!

 

Noteworthy News

Revisit the top 5 most-read news stories published by the NMD4C over the past year!

  1. COVID-19 and Neuromuscular Patients
  2. Current State of Spinal Muscular Atrophy (SMA) in Canada Webinar Report
  3. COVID-19 Resources Care Recommendations for Home Based Ventilation Patients
  4. Pulmonary support for people with myotonic dystrophy during COVID-19 pandemic
  5. Letter to provincial governments regarding SMA therapy outcome measures

 

Early Career Holiday Reading

The NMD4C is fortunate to have so many members who are in the early stages of their careers; we believe that providing training and support to these members will impact the knowledge and understanding of NMD for the next generation of clinicians and researchers.

Throughout 2020 we have featured several of our members through our early career blogs; find the full list of blogs here! From finding inspiration to offering new perspectives, the blogs provide insight into the challenges and triumphs of navigating a nascent career in science and medicine.

 

2020 Webinar Wrap Up

With our partner, Muscular Dystrophy Canada, we wrapped our incredible slate of webinars in 2020 with December’s Up and Coming Stars in NMD, where we heard from several young researchers and clinicians who are engaged in exciting projects in NMD.

We are planning to build on these successful webinars in 2021 and will resume January 5th, with All You Need to Know about CMT – Clinical Updates, and NMD Case Rounds and Genetic Neuropathies in the following months!

Check out reports of past webinars in 2020 from NMD4C and our partners:

canada-nmd4c

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.